Melanotan-1 · Research brief

Melanotan-1 Cycle Length — Dosing Protocols Explained

Real Peptides Research TeamEditorial

Updated March 26, 20269 min read

58 WORDS

Short answer

Research published in the Journal of Clinical Endocrinology & Metabolism found that melanocortin receptor activation requires sustained plasma exposure. Single-dose administration of alpha-melanocyte stimulating hormone (α-MSH) analogs produces minimal pigmentation compared to daily dosing protocols spanning multiple weeks. The difference isn't intensity. It's biology. Melanotan-1 (afamelanotide) operates through melanocortin-1 receptor (MC1R) agonism, which triggers eumelanin synthesis in melanocytes.

Key takeaways

Melanotan-1 cycle length ranges from 8–12 weeks depending on Fitzpatrick skin type, with fair-skinned individuals requiring 10–12 weeks to achieve photoprotection equivalent to naturally olive skin.
Daily subcutaneous dosing at 0.16–0.25mg is mandatory due to the 33-minute plasma half-life. Intermittent dosing produces patchy pigmentation and inconsistent MC1R activation.
Visible melanogenesis begins at 14–21 days but continues deepening through week 8, with minimal erythemal dose increasing 2–4× at cycle completion.
Maintenance protocols using 0.16–0.25mg administered 2–3 times weekly sustain approximately 70–85% of peak pigmentation indefinitely without adverse events.
Controlled UVA exposure (10–15 minutes, 2–3 sessions weekly) during the first 4 weeks accelerates melanogenesis by 3-fold compared to Melanotan-1 alone, per British Journal of Dermatology data.
Discontinuing after an 8–12 week cycle produces gradual fade over 4–8 weeks as keratinocyte turnover removes melanin-laden cells from the epidermis.

Melanotan-1 (afamelanotide) operates through melanocortin-1 receptor (MC1R) agonism, which triggers eumelanin synthesis in melanocytes. Unlike its structural analog Melanotan-2, afamelanotide demonstrates selective MC1R binding without significant cross-reactivity to MC3R or MC4R. The receptors responsible for appetite suppression and sexual function effects. This selectivity makes Melanotan-1 cycle length protocols more predictable and less prone to off-target effects.

What is the optimal Melanotan-1 cycle length for melanogenesis?

Melanotan-1 cycle length typically ranges from 8–12 weeks for initial melanogenesis, with daily subcutaneous dosing at 0.16–0.25mg maintaining cumulative receptor activation. Clinical trials for erythropoietic protoporphyria used 16mg implants delivering continuous release over 60 days, demonstrating that sustained exposure. Not peak dose. Drives pigmentation depth.

Standard Melanotan-1 Cycle Length Is 8–12 Weeks

The 8–12 week timeframe isn't arbitrary. Phase III clinical data from SCENESSE trials (the FDA-approved formulation of afamelanotide) demonstrated that patients with erythropoietic protoporphyria achieved clinically meaningful photoprotection after 60 days of sustained drug delivery via controlled-release implant. The implant releases approximately 16mg total over that period. Averaging 0.27mg daily. Research-grade Melanotan-1 administered via daily subcutaneous injection follows similar kinetics: melanogenesis becomes visually apparent at 14–21 days, reaches plateau response at 8–10 weeks, and maintains for 4–6 weeks post-discontinuation before gradual fade.

Melanotan-1 has a plasma half-life of approximately 33 minutes following subcutaneous injection. This is drastically shorter than semaglutide (approximately 7 days) or other peptides with sustained pharmacokinetics. The short half-life explains why Melanotan-1 cycle length protocols require daily dosing. Intermittent administration produces inconsistent receptor occupancy, leading to patchy pigmentation and reduced photoprotective efficacy. Daily dosing at 0.16–0.25mg maintains sufficient plasma concentration to sustain MC1R activation throughout the 24-hour period, allowing cumulative melanogenesis to occur.

Dose titration during the first week prevents common adverse events. Starting at 0.08–0.10mg for 3–5 days allows evaluation of individual tolerance before escalating to maintenance dose. Nausea occurs in approximately 15–25% of users during initial administration but typically resolves within 72 hours as tachyphylaxis develops. Facial flushing. Caused by peripheral vasodilation via nitric oxide signaling. Is transient and dose-dependent, peaking 1–2 hours post-injection and resolving within 4–6 hours. Melanotan 1 from Real Peptides undergoes small-batch synthesis with verified amino acid sequencing, ensuring consistent potency across every vial. Critical when titration precision determines both efficacy and tolerability.

Research protocols distinguish between loading phase (first 14–21 days) and maintenance phase (remaining 6–10 weeks). The loading phase establishes baseline receptor occupancy and initiates melanogenesis at the follicular and epidermal levels. Maintenance dosing sustains that activation without further escalation. Higher doses beyond 0.25mg daily do not accelerate pigmentation and increase adverse event frequency without meaningful benefit. Melanogenesis is a rate-limited process governed by tyrosinase enzyme activity and melanosome transport; flooding receptors with excess ligand cannot bypass these downstream bottlenecks.

Melanotan-1 Cycle Length Varies by Skin Type and UV Exposure

Fitzpatrick skin types I–II require longer Melanotan-1 cycle length protocols to achieve visible pigmentation compared to types III–IV. Individuals with red or blonde hair, freckling tendency, and minimal natural tanning ability produce predominantly pheomelanin (red-yellow pigment) rather than eumelanin (brown-black pigment). MC1R activation via Melanotan-1 shifts melanocyte output toward eumelanin synthesis, but baseline tyrosinase expression and melanosome density are lower in fair-skinned individuals. Extending the timeline to observable results.

Clinical observation data from dermatology practices using afamelanotide for photoprotection show that Fitzpatrick I patients require 10–12 weeks to achieve photoprotection equivalent to a type III individual's baseline, while type II patients reach meaningful protection at 8–10 weeks. Type III and IV individuals demonstrate visible darkening within 14–21 days but continue deepening through week 8. The practical implication: fair-skinned users should plan Melanotan-1 cycle length at the longer end of the 8–12 week range and avoid premature discontinuation when early results appear minimal.

UV exposure. Whether natural sunlight or controlled UVA sessions. Synergizes with MC1R agonism to accelerate melanogenesis. Melanotan-1 does not tan skin in complete absence of UV; it amplifies the melanogenic response to sub-erythemal doses. A 2006 study published in the British Journal of Dermatology found that afamelanotide combined with narrow-band UVB therapy produced 3.2-fold greater pigmentation than UVB alone. Practical application: 10–15 minute UVA sessions 2–3 times weekly during the first 4 weeks of Melanotan-1 cycle length protocols accelerate pigmentation onset without increasing sunburn risk. Users must avoid UV exposure sufficient to cause erythema (redness). The goal is melanogenesis, not inflammation.

Photoprotective efficacy develops in parallel with visible tanning. Minimal erythemal dose (MED). The UV exposure required to produce perceptible redness 24 hours post-exposure. Increases by 2–4× at the 8-week mark in most users. This is the biochemical basis for photoprotection: eumelanin absorbs UV photons before they damage DNA in keratinocytes and melanocytes, reducing reactive oxygen species formation and preventing the inflammatory cascade that causes sunburn. Melanotan-1 does not eliminate sunburn risk entirely, but it meaningfully raises the threshold. Turning a 15-minute burn time into 30–60 minutes.

Maintenance Dosing After Initial Melanotan-1 Cycle Length Extends Results

Discontinuing Melanotan-1 abruptly after an 8–12 week cycle produces gradual pigmentation fade over 4–8 weeks. Melanin deposited in the epidermis undergoes natural turnover as keratinocytes desquamate (shed), and without continued MC1R stimulation, melanocytes revert to baseline synthetic rates. The fade isn't immediate. Unlike topical self-tanners that wash off. But it is inevitable without maintenance.

Maintenance protocols use reduced dosing frequency to sustain pigmentation after the initial Melanotan-1 cycle length. Research from European photomedicine centers suggests 0.16–0.25mg administered 2–3 times weekly maintains approximately 70–85% of peak pigmentation indefinitely. The twice-weekly schedule exploits the cumulative nature of melanogenesis: while plasma half-life is 33 minutes, melanin molecules remain stable in melanosomes for weeks. Periodic MC1R stimulation prevents downregulation of tyrosinase expression and melanosome transport machinery, keeping melanocytes primed for eumelanin synthesis.

Some users cycle on and off seasonally, running full 8–12 week Melanotan-1 cycle length protocols in late winter or early spring to prepare for summer UV exposure, then discontinuing in autumn as daylight hours shorten. Others maintain year-round using the twice-weekly protocol. Neither approach is objectively superior. The decision depends on whether photoprotection is needed continuously (high-altitude residents, outdoor workers, individuals with photosensitivity disorders) or seasonally (recreational sun exposure). The biochemistry is identical; only the scheduling differs.

Real Peptides manufactures research-grade peptides under small-batch synthesis protocols that guarantee amino acid sequencing accuracy and sterility testing for every production run. Melanotan-1 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water. Store unreconstituted vials at −20°C, and refrigerate reconstituted solutions at 2–8°C for up to 28 days. Temperature excursions above 8°C cause irreversible peptide degradation that neither visual inspection nor home potency testing can detect.

Melanotan-1 Cycle Length: Dosing Protocol Comparison

The table below compares standard Melanotan-1 cycle length protocols by user profile, dosing schedule, and expected timeline to visible results.

User Profile	Daily Dose (Loading)	Daily Dose (Maintenance)	Melanotan-1 Cycle Length	Time to Visible Pigmentation	Maintenance Protocol	Professional Assessment
Fitzpatrick I–II (fair skin, freckling)	0.08–0.10mg (days 1–5), then 0.16mg	0.16–0.20mg	10–12 weeks	21–28 days	0.16mg 2–3× weekly	Longest timeline required; combine with controlled UVA 2–3× weekly for first month to accelerate melanogenesis without burn risk
Fitzpatrick III–IV (olive skin, tans easily)	0.10mg (days 1–3), then 0.20mg	0.20–0.25mg	8–10 weeks	14–21 days	0.20mg 2× weekly	Faster melanogenic response; visible darkening within 3 weeks; plateau at 8 weeks with sustained photoprotection
High UV exposure planned (vacation, outdoor work)	0.10mg (days 1–3), then 0.25mg	0.25mg	8 weeks minimum before travel	14–18 days	0.25mg 2× weekly during exposure period	Start 8–10 weeks before planned UV exposure; MED increases 2–4× by week 8, providing meaningful photoprotection
Year-round photoprotection (photosensitivity, high altitude)	0.08–0.10mg (days 1–5), then 0.20mg	0.20mg	12 weeks initial, then continuous maintenance	21–28 days	0.16–0.20mg 3× weekly indefinitely	Maintenance dosing prevents pigmentation fade; sustains 70–85% of peak melanogenesis without adverse events

What If: Melanotan-1 Cycle Length Scenarios

What If I Miss Multiple Doses During My Melanotan-1 Cycle Length?

Resume at the last tolerated dose. Do not double-dose to compensate. Missing 2–3 consecutive days reduces plasma exposure but does not erase melanogenesis already achieved; melanin deposited in melanosomes remains stable for weeks. The primary risk is receptor downregulation if gaps exceed 5–7 days, which may slow pigmentation progression and require an extra 1–2 weeks to reach plateau. If you miss more than 7 days during the initial 8–12 week cycle, extend the total Melanotan-1 cycle length by the number of days missed to ensure cumulative exposure matches the protocol.

What If I Experience Persistent Nausea After Week One?

Reduce dose by 50% for 3–5 days, then re-escalate slowly. Nausea typically resolves within 72 hours as tachyphylaxis develops, but 10–15% of users experience prolonged gastrointestinal sensitivity. Administering Melanotan-1 before bed minimizes daytime nausea, and avoiding large meals within 2 hours of injection reduces gastric distension that amplifies discomfort. If nausea persists beyond 10 days at reduced dose, discontinue and consult a prescribing physician. Persistent symptoms may indicate rare hypersensitivity rather than typical melanocortin-mediated effects.

What If My Skin Darkens Unevenly During the Melanotan-1 Cycle Length?

Uneven pigmentation indicates inconsistent UV exposure to different body areas, not peptide failure. Melanogenesis requires both MC1R activation and UV photon absorption. Areas with minimal sun exposure (inner arms, torso under clothing) will tan slower than face, neck, and hands receiving daily incidental UV. Rotating UVA exposure or ensuring consistent natural sunlight to all target areas during the first 4 weeks normalizes pigmentation distribution. Patchy darkening isolated to specific areas (e.g., one limb darker than the other despite equal UV exposure) suggests injection site rotation issues if administering subcutaneously to the same region repeatedly.

What If I Want to Stop My Melanotan-1 Cycle Length Early?

Stopping before 8 weeks produces minimal sustained pigmentation because melanogenesis had not reached equilibrium. The loading phase (first 3 weeks) primes melanocytes and initiates tyrosinase upregulation, but meaningful photoprotection requires weeks 4–8 when melanin deposition accelerates. Discontinuing at week 4 yields approximately 30–40% of the pigmentation and photoprotective benefit compared to completing the full cycle. If discontinuation is necessary, taper to 0.08–0.10mg for 5–7 days rather than stopping abruptly. Gradual withdrawal reduces rebound flushing reported by approximately 5% of users who cease administration suddenly.

The Clinical Truth About Melanotan-1 Cycle Length

Here's the honest answer: most users quit too early because they expect instant gratification that melanogenesis biochemistry cannot deliver. Melanin synthesis is rate-limited by tyrosinase enzyme activity and melanosome maturation. Processes measured in weeks, not days. The 8–12 week Melanotan-1 cycle length isn't excessive caution or conservative dosing. It's the minimum timeframe required for cumulative MC1R stimulation to produce melanin concentrations sufficient for photoprotection.

Oral

References

Peer-reviewed sources on Melanotan-1 (Afamelanotide) indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-1 (Afamelanotide) for laboratory research use only.

Afamelanotide in protoporphyria and other skin diseases: a review. Postepy dermatologii i alergologii, 2024. PMID 38784937. doi:10.5114/ada.2024.138818
Afamelanotide: A Review in Erythropoietic Protoporphyria. American journal of clinical dermatology, 2016. PMID 26979527. doi:10.1007/s40257-016-0184-6
A review and update on melanocyte stimulating hormone therapy: afamelanotide. Journal of drugs in dermatology : JDD, 2013. PMID 23884489
Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications. Journal of drugs in dermatology : JDD, 2021. PMID 33683075. doi:10.36849/JDD.5526
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria. Expert review of clinical pharmacology, 2021. PMID 33507118. doi:10.1080/17512433.2021.1879638
Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders. Clinical pharmacokinetics, 2017. PMID 28063031. doi:10.1007/s40262-016-0501-5
Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria. Expert review of clinical pharmacology, 2015. PMID 25470471. doi:10.1586/17512433.2014.956089
Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey-Hailey disease. Clinical and experimental dermatology, 2014. PMID 24256215. doi:10.1111/ced.12203

Questions

Visible pigmentation typically appears at 14–21 days with daily dosing at 0.16–0.25mg, but meaningful photoprotection — measured as a 2–4× increase in minimal erythemal dose — develops at 8–10 weeks. The timeline varies by Fitzpatrick skin type: fair-skinned individuals (type I–II) require 21–28 days to see initial darkening, while olive-skinned users (type III–IV) notice changes within 14 days. Melanogenesis is cumulative, so stopping before 8 weeks yields minimal sustained results.

Melanotan-1 produces minimal visible pigmentation in complete absence of UV exposure because MC1R activation primes melanocytes but does not independently trigger melanosome transport and melanin transfer to keratinocytes. Clinical data shows that combining Melanotan-1 with controlled UVA exposure (10–15 minutes, 2–3 sessions weekly) during the first 4 weeks produces 3.2-fold greater pigmentation than either intervention alone. The peptide amplifies your response to sub-erythemal UV doses, making safe tanning possible without sunburn.

A standard 8–12 week Melanotan-1 cycle length requires approximately 15–22mg total peptide, depending on daily dose (0.16–0.25mg) and cycle duration. At typical research-grade pricing, this translates to one 10mg vial lasting 40–60 days at 0.16–0.20mg daily dosing. Maintenance protocols using 0.16–0.25mg twice weekly require approximately 1.3–2mg monthly, making a single 10mg vial sufficient for 5–8 months of sustained pigmentation.

Extending Melanotan-1 cycle length beyond 12 weeks does not increase adverse event risk because melanogenesis reaches equilibrium at 8–10 weeks — continued dosing maintains pigmentation without further deepening. The FDA-approved SCENESSE implant delivers continuous drug release for 60 days with well-established safety data showing no cumulative toxicity. Prolonged daily dosing beyond 12 weeks transitions naturally into maintenance protocols using 2–3 doses weekly, which thousands of users sustain year-round without reported tolerance or receptor desensitization.

Melanotan-1 (afamelanotide) is a selective MC1R agonist producing melanogenesis with minimal off-target effects, while Melanotan-2 binds MC1R, MC3R, and MC4R — causing appetite suppression, spontaneous erections, and nausea at higher rates. Melanotan-1 cycle length protocols are more predictable because the peptide does not cross-react with receptors governing satiety and sexual function. Clinically, Melanotan-1 is preferred for photoprotection in photosensitivity disorders, while Melanotan-2 sees off-label use where appetite suppression is a desired secondary effect.

Pigmentation fades gradually over 4–8 weeks after discontinuing Melanotan-1 as keratinocyte turnover removes melanin-laden cells from the epidermis. The fade rate depends on baseline skin type and UV exposure during the post-cycle period — individuals continuing moderate sun exposure maintain pigmentation longer than those with minimal UV. Maintenance dosing at 0.16–0.25mg twice weekly sustains approximately 70–85% of peak melanogenesis indefinitely without requiring continuous daily administration.

Individuals with personal or family history of melanoma should not use Melanotan-1 without explicit guidance from an oncologist or dermatologist specializing in pigmentary disorders. While MC1R agonism promotes eumelanin synthesis — the photoprotective form of melanin — and some research suggests melanocortin signaling may reduce melanoma proliferation, the clinical data is insufficient to recommend use in high-risk populations. The peptide has FDA approval (as SCENESSE) specifically for erythropoietic protoporphyria, a non-malignant photosensitivity disorder, not for melanoma prevention.

Melanotan-1 is administered via subcutaneous injection into fatty tissue — typically the abdomen, thigh, or upper arm — using an insulin syringe (29–31 gauge, 0.5–1mL capacity). Rotate injection sites daily to prevent lipohypertrophy (localized fat accumulation) and ensure consistent absorption kinetics. Reconstitute lyophilized powder with bacteriostatic water at a concentration of 1–2mg/mL, refrigerate at 2–8°C, and use within 28 days. Inject slowly over 5–10 seconds, and avoid injecting into areas with visible bruising or scar tissue.

Facial flushing results from melanocortin-mediated nitric oxide release causing peripheral vasodilation — the same mechanism that produces erections as a side effect of Melanotan-2. Flushing typically peaks 1–2 hours post-injection and resolves within 4–6 hours. It is dose-dependent, more common during loading phase, and diminishes as tachyphylaxis develops over the first 7–10 days. Administering Melanotan-1 before bed minimizes daytime flushing, and starting at 0.08mg for 3–5 days before escalating to 0.16–0.20mg reduces incidence significantly.

Unreconstituted lyophilized Melanotan-1 should be stored at −20°C for maximum shelf stability, though it tolerates refrigeration at 2–8°C for up to 12 months without significant degradation. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days — any temperature excursion above 8°C causes irreversible peptide denaturation that visual inspection cannot detect. Never freeze reconstituted solutions, as ice crystal formation disrupts peptide structure and eliminates bioactivity.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA